300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Film
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Blockchain
Facebook
Social Network
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Music
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Manufacturing
FinTech
Finance
Digital Media
Art
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Real Estate
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Sporting Goods
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Armenia
Colombia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Paul McCreadie, Managing Partner and Chief Operating Officer at Arboretum Ventures

Paul McCreadie

Managing Partner and Chief Operating Officer @ Arboretum Ventures

Detroit, United States

Paul McCreadie is a Series C investor at Arboretum Ventures in Detroit focused on Health Care and Medical. Paul McCreadie is based out of Ann Arbor, Michigan and is the Managing Partner & COO of Arboretum Ventures. Paul previously worked at Cardiac Dimensions as a Board Member. Paul McCreadie attended the University of Michigan Ross School of Business.

Total investments:
12
Last investment:
Lead investor:
50%

Last updated:

Industries Paul McCreadie invests in

Health CareMedicalBiotechnologyPharmaceuticalMedical Device

Stages Paul McCreadie invests in

Series CSeries DSeries ASeries BPrivate Equity

Countries Paul McCreadie invests in

United StatesIsrael

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Health Care 8 (67%)
  • Medical 5 (42%)
  • Biotechnology 3 (25%)
  • Pharmaceutical 3 (25%)
  • Medical Device 2 (17%)
See all 11 industries →

Stage

  • Series C 3 (25%)
  • Series D 3 (25%)
  • Series A 1 (8%)
  • Series B 1 (8%)
  • Private Equity 1 (8%)
See all 6 stages →

Country

  • United States 7 (58%)
  • Israel 1 (8%)

Investments

CompanyDescriptionRoundLinks
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. $57.5M / Series D / Jun 05, 2025
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. $68M / Series D / Oct 08, 2024
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. $30.4M / Series D / Sep 13, 2022
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. $60M / Series C / Sep 15, 2021
BioIQ also known as Jentryx is a health improvement technology company that has implemented the industry’s first integrated, customizable and measurable approach to optimizing investments in corporate health and wellness programs. The company’s unique health screening platform, ecosystem of health improvement tools, and proven methodology forobtaining quantifiable wellness insights are serving beneficiaries across the United States. BioIQ works with some of the largest employers and health companies in the nation and has launched over 3,000 successful health improvement programs since its inception in 2005. $26.5M / Venture - Series Unknown / Mar 22, 2018
ArborMetrix is a performance measurement for Acute and Specialty Care. Based on its industry-changing research, ArborMetrix delivers outcomes-based, risk- and reliability-adjusted clinical intelligence, which provides actionable insights for Hospitals, Health Plans, ACOs, Physicians, Societies, and Collaboratives. Their leading healthcareanalytics solutions are proven to deliver targeted, clinically-deep insights that improve clinical outcomes, optimize financial performance, increase stakeholder value, and measure the real-world effectiveness of treatments and procedures, as well as medical device technologies and pharmaceuticals.It was founded in 2011 and headquartered in Ann Arbor, Michigan. $6.9M / Series B / Mar 31, 2016
Delphinus Medical Technologies develops, commercializes, sells, and services the breast cancer screening solutions to hospitals and imaging clinics in the United States and internationally. It commercializes SoftVue, a three-dimensional and tomographic ultrasound imaging and risk assessment device that examines women's breasts for the presenceof benign and/or malignant masses, assesses breast cancer risks, diagnoses breast diseases, and monitors therapy. The company was founded in 2009 and is based in Detroit, Michigan. $39.5M / Series C / Sep 10, 2015
Rethink Autism's solution is a web-based autism treatment platform that combines a proven treatment methodology (ABA) with a proven method of instruction (video modeling). Using technology to deliver clinical best practice treatment programs anywhere, Rethink Autism has created a unique online service providing parents and organizations withtraining for implementing treatment, tools for evaluating an individual child's needs, a comprehensive video-based curriculum with 1,200+ teaching steps, data tracking systems for measuring progress and automating case management, and online professional support. No other product or company combines a dynamic video-based curriculum, data management tools and professional support, all on a single easy-to-use web-based platform. $10M / Series C / Aug 18, 2014
Adavium Medical is a medical equipment and diagnostics company aimed at bringing commercial sophistication to a highly fragmented market. The Company was formed with the intent to commercialize the most innovative portfolio of medical device and diagnostics products in Brazil. Adavium Medical portfolio today is made up of products that wecommercialize on behalf of leading international companies.Adavium Medical assembled an experienced team of more than 300 employees that ensure that its fully-integrated commercial platform operates at world-class standards.Adavium Medical have the largest customer base across premium and “long tail” customers of any medical equipment and/or diagnostics company in Brazil, with more than 2,500 customers respectively in medical equipment and diagnostics. This is exponentially more than the average distributor or multinational in the region.The company was founded in 2011 and is headquartered in Sao Paulo, Brazil. $20M / Private Equity / Sep 04, 2013
ArborMetrix is a performance measurement for Acute and Specialty Care. Based on its industry-changing research, ArborMetrix delivers outcomes-based, risk- and reliability-adjusted clinical intelligence, which provides actionable insights for Hospitals, Health Plans, ACOs, Physicians, Societies, and Collaboratives. Their leading healthcareanalytics solutions are proven to deliver targeted, clinically-deep insights that improve clinical outcomes, optimize financial performance, increase stakeholder value, and measure the real-world effectiveness of treatments and procedures, as well as medical device technologies and pharmaceuticals.It was founded in 2011 and headquartered in Ann Arbor, Michigan. $7M / Series B / Jul 16, 2013
See all 12 investments →

Co-Investors

Arboretum Ventures

About Arboretum Ventures

VC Fund · Ann Arbor, United States

Arboretum Ventures is a Michigan-based venture capital firm. It specializes in seed-stage, early-stage, mid-stage investments, and growth capital. The company seeks to invest in healthcare sector with a focus on services, medical devices, diagnostics; healthcare information technology, therapeutics, technology based healthcare services, and lifescience tools. The firm invests throughout the United States with a focus on Midwest and Michigan. It seeks to invest in companies with equity investment between $5 million and $15 million.Arboretum Ventures Jan Garfinkle in 2002 and is headquartered in Michigan.

Arboretum Ventures Contacts

NameEmailPhoneSocials
Paul McCreadie
Paul McCreadie Managing Partner and Chief Operating Officer
Robert Cesaro
Robert Cesaro Associate
Tim Petersen
Tim Petersen Founder and Managing Partner
Amanda Goldstein
Amanda Goldstein Executive Assistant
George Dunbar
George Dunbar Venture Partner

Sign up to unlock verified contacts

Unlock Contacts

See all 10 contacts →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Film
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Blockchain
Facebook
Social Network
B2B
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Music
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Manufacturing
FinTech
Finance
Digital Media
Art
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Real Estate
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Sporting Goods
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Brazil
LATAM
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Puerto Rico
Poland
Cameroon
Guernsey
Armenia
Colombia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Botswana
Seychelles
Paraguay
South Africa
Canada
Ireland
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Paul McCreadie invest in?

Paul McCreadie invests primarily in Health Care, Medical and Biotechnology startups, most often at Series C and Series D stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact Paul McCreadie?

Public channels for Paul McCreadie include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Paul McCreadie last invest?

The most recent investment recorded for Paul McCreadie closed in Jun 2025. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Paul McCreadie Paul McCreadie Find email